Table 4.
Univariate and multivariate analyses of progression-free survival of EGFR mutated NSCLC with 150 mg erlotinib.
| N patients | Univariate KaplaneMeier analyses | Multivariate Cox regression analyses | ||||||
|---|---|---|---|---|---|---|---|---|
| Median PFS | 95% CI | p value | HR | 95% CI | p value | |||
| Clinical factors | ||||||||
| Age | HR per year increase= 0.979 | 0.954–1.006 | 0.128 | 0.974 | 0.936–1.012 | 0.179 | ||
| Body surface area | HR per year increase= 1.020 | 1.004–1.036 | 0.013 | 1.042 | 1.011–1.074 | 0.008 | ||
| Sex | Male | 52 | 18 | 13.9–22.1 | 0.231 | 1 | ||
| Female | 35 | 15 | 13.6–16.4 | 0.375 | 0.113–1.249 | 0.110 | ||
| Smoking status | Never | 57 | 19 | 15.7–22.3 | 0.027 | 1 | ||
| Former | 16 | 16 | 10.9–22.1 | 2.529 | 0.695–9.205 | 0.159 | ||
| Present | 14 | 15 | 14.1–15.9 | 5.317 | 1.184–22.382 | 0.029 | ||
| Clinical stage | III | 24 | 24 | 7.8–40.2 | 0.204 | 1 | ||
| IV | 63 | 16 | 13.4–18.6 | 2.004 | 0.769–5.525 | 0.155 | ||
| ECOG PS | 0 | 34 | 15 | 11.3–18.7 | 0.203 | 1 | ||
| 1 | 48 | 18 | 15.6–20.4 | 1.257 | 0.507–3.115 | 0.621 | ||
| 2 | 5 | 12 | 6.8–17.2 | 3.747 | 0.579–24.244 | 0.166 | ||
| EGFR mutation status | Exon 19 deletion | 58 | 18 | 15.1–20.9 | 0.197 | 1 | ||
| Exon 21 L858R | 29 | 15 | 11.0–19.0 | 1.318 | 0.901–1.927 | 0.155 | ||
| Genetic factors | ||||||||
| rs1048943(CYP1A1) | A/A | 11 | 15 | 8.8–21.2 | 0.030 | 1 | ||
| A/G | 25 | 18 | 16.1–20.0 | 0.226 | 0.055–0.923 | 0.038 | ||
| G/G | 51 | 18 | 13.9–22.1 | 0.528 | 0.149–1.869 | 0.322 | ||
| rs1065852(CYP2D6) | G/G | 36 | 17 | 13.2–20.8 | 0.982 | 1 | ||
| G/A | 34 | 18 | 13.4–22.6 | 0.804 | 0.358–1.805 | 0.596 | ||
| A/A | 17 | 15 | 9.5–20.5 | 1.891 | 0.756–4.732 | 0.174 | ||
| rs2242480(CYP3A4) | C/C | 40 | 17 | 14.6–19.4 | 0.802 | 1 | ||
| C/T | 44 | 15 | 6.9–23.1 | 1.532 | 0.541–4.377 | 0.422 | ||
| T/T | 3 | 15 | 11.8–18.2 | 0.742 | 0.075–7.348 | 0.799 | ||
| rs776746(CYP3A5) | C/C | 30 | 18 | 15.6–20.4 | 0.831 | 1 | ||
| C/T | 46 | 15 | 13.5–16.5 | 0.649 | 0.217–1.934 | 0.437 | ||
| T/T | 11 | 23 | 4.1–41.9 | 0.313 | 0.065–1.505 | 0.147 | ||
| rs762551(CYP1A2) | C/C | 11 | 15 | 13.3–16.7 | 0.097 | 1 | ||
| C/A | 38 | 18 | 14.8–21.2 | 0.784 | 0.317–1.937 | 0.597 | ||
| A/A | 38 | 31 | 0.408 | 0.131–1.266 | 1.121 | |||
| rs2470890(CYP1A2) | C/C | 74 | 17 | 14.4–19.6 | 0.783 | 1 | ||
| C/T | 12 | 17 | 12.9–21.1 | 1.196 | 0.435–3.287 | 0.728 | ||
| T/T | 1 | 16 | 0.092 | 0.004–2.229 | 0.142 | |||
| rs1045642(ABCB1) | G/G | 34 | 16 | 13.6–18.4 | 0.857 | 1 | ||
| G/A | 39 | 19 | 13.9–24.1 | 0.935 | 0.361–2.514 | 0.923 | ||
| A/A | 14 | 17 | 12.3–21.7 | 0.659 | 0.205–2.123 | 0.485 | ||
| rs1128503(ABCB1) | G/G | 6 | 18 | 14.8–21.2 | 0.158 | 1 | ||
| G/A | 41 | 15 | 12.4–17.6 | 0.764 | 0.346–1.685 | 0.504 | ||
| A/A | 40 | 13 | 10.6–15.4 | 0.920 | 0.243–3.479 | 0.903 | ||
| rs2231142(ABCG2) | G/G | 48 | 16 | 13.2–18.8 | 0.598 | 1 | ||
| G/T | 32 | 20 | 17.0–23.0 | 1.297 | 0.602–2.794 | 0.506 | ||
| T/T | 7 | 15 | 0.754 | 0.131–4.352 | 0.752 | |||
| rs2622604(ABCG2) | C/C | 52 | 16 | 13.5–18.5 | 0.850 | 1 | ||
| C/T | 32 | 19 | 14.5–23.5 | 0.908 | 0.433–1.905 | 0.799 | ||
| T/T | 3 | 23 | 2.030 | 0.426–9.662 | 0.374 | |||
| rs7699188(ABCG2) | G/G | 77 | 17 | 14.8–19.2 | 0.698 | 1 | ||
| G/A | 10 | 16 | 9.3–22.7 | 0.730 | 0.226–2.362 | 0.559 | ||